Jeffrey R Currier
Overview
Explore the profile of Jeffrey R Currier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waldran M, Kurtz E, Gebo C, Rooney T, Middleton F, Roy N, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae720.
PMID: 39758748
Background: Dengue virus (DENV) is an arboviral pathogen found in >100 countries and a source of significant morbidity and mortality. While the mechanisms underpinning the pathophysiology of severe Dengue are...
2.
Ehrenberg P, Geretz A, Volcic M, Izumi T, Yum L, Waickman A, et al.
bioRxiv
. 2024 Nov;
PMID: 39605411
Elimination of latent HIV-1 is a major goal of AIDS research but the host factors determining the size of these reservoirs are poorly understood. Here, we investigated whether differences in...
3.
Gebo C, Hardy C, McElvany B, Graham N, Lu J, Moradpour S, et al.
PLoS Pathog
. 2024 Oct;
20(10):e1012683.
PMID: 39480886
Dengue virus (DENV) is the causative agent of dengue, a mosquito-borne disease that represents a significant and growing public health burden around the world. A unique pathophysiological feature of dengue...
4.
Mandaric S, Friberg H, Saez-Llorens X, Borja-Tabora C, Biswal S, Escudero I, et al.
NPJ Vaccines
. 2024 Oct;
9(1):192.
PMID: 39420169
As robust cellular responses are important for protection against dengue, this phase 2 study evaluated the kinetics and phenotype of T cell responses induced by TAK-003, a live-attenuated tetravalent dengue...
5.
Lyke K, Chua J, Koren M, Friberg H, Gromowski G, Rapaka R, et al.
Lancet Infect Dis
. 2024 Apr;
24(8):896-908.
PMID: 38679035
Background: Dengue human infection models (DHIMs) are important tools to down-select dengue vaccine candidates and establish tetravalent efficacy before advanced clinical field trials. We aimed to provide data for the...
6.
Waickman A, Newell K, Lu J, Fang H, Waldran M, Gebo C, et al.
Nat Microbiol
. 2024 Apr;
9(5):1356-1367.
PMID: 38561497
Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of...
7.
Sanchez-Vargas L, Mathew A, Salje H, Sousa D, Casale N, Farmer A, et al.
J Infect Dis
. 2024 Mar;
230(5):1147-1156.
PMID: 38478732
Background: Dengue virus (DENV) nonstructural protein 1 (NS1) has multiple functions within infected cells, on the cell surface, and in secreted form, and is highly immunogenic. Immunity from previous DENV...
8.
Sankhala R, Lal K, Jensen J, Dussupt V, Mendez-Rivera L, Bai H, et al.
Nat Commun
. 2024 Jan;
15(1):200.
PMID: 38172512
The repeat emergence of SARS-CoV-2 variants of concern (VoC) with decreased susceptibility to vaccine-elicited antibodies highlights the need to develop next-generation vaccine candidates that confer broad protection. Here we describe...
9.
Sankhala R, Dussupt V, Chen W, Bai H, Martinez E, Jensen J, et al.
Structure
. 2023 Dec;
32(2):131-147.e7.
PMID: 38157856
Given the continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs), immunotherapeutics that target conserved epitopes on the spike (S) glycoprotein have therapeutic advantages. Here,...
10.
Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Curtis D, et al.
EBioMedicine
. 2023 Oct;
97:104815.
PMID: 37793212
Background: Complex patterns of cross-reactivity exist between flaviviruses, yet there is no precise understanding of how sequential exposures due to flavivirus infections or vaccinations impact subsequent antibody responses. Methods: We...